Sanofi: FDA approves Libtayo (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of =50%
N=356
a
14 months
Median (95% CI)
b Based on stratified proportional hazards model
An additional prespecified analysis was performed in 563 patients with proven PD-L1 expression of =50%, according to the FDA-approved assay, and is described in the updated labeling of the FDA-approved assay (and also recently
published (https://www.sanofi.com/en/media-room/press-releases/2021/2021-02-12-07-00-00) in
The Lancet). This analysis showed that Libtayo reduced the risk of death by 43% compared to chemotherapy, with additional efficacy results as follows:
Endpoints
This is the third approval for Libtayo, following approvals as the first immunotherapy for patients with advanced basal cell carcinoma and as the first systemic treatment for advanced cutaneous squamous cell carcinoma.<br />
/PRNewswire/ Libtayo was superior in extending overall survival compared to chemotherapy in a pivotal trial that allowed for certain disease characteristics.
Print Hospital executives and physicians cut the ribbon at the new Maternal and Newborn Care Unit at NewYork-Presbyterian Hudson Valley Hospital. Photo Credit:
NewYork-Presbyterian Hudson Valley Hospital
NewYork-Presbyterian Hudson Valley Hospital Laila was the first baby born in the new maternity unit at NYP Hudson Valley Hospital. Photo Credit:
NewYork-Presbyterian Hudson Valley Hospital
On January 20, NewYork-Presbyterian Hudson Valley Hospital celebrated the opening of its Maternal & Newborn Care Unit, designed to enhance the care and comfort of expectant moms and their newborns and provide the best patient experience before, during and after childbirth.
Located on the second floor of NewYork-Presbyterian Hudson Valley Hospital, the center features bright, private postpartum rooms, each with a bathroom, shower, and a comfortable bed for a partner to sleep that allows for family-focused support and